July 2019 Blog Posts (1)
Todlers Language and Speech Delays
The development of the speech of a young child (1-3 years) is a very important stage in mastering the native language. Speech crumbs not just booming, it is formed. Therefore, assistance to the child in the development of talking in this period is particularly relevant. Properly organized communication and classes not only spur the development of the child's language, but also help to compensate for possible irregularities, for example, a lag in speech…
ContinueAdded by Tata Nech on July 24, 2019 at 4:17am — No Comments
Featured Blog Posts
- PPMD Designates UC Davis a Certified Duchenne Care Center
- PPMD Working with FDA to Plan Landmark Pediatric Advisory Committee Meeting to Improve Clinical Trial Experience
- PPMD's Duchenne Drug Development Roundtable Meeting Series, Part 3: Clinical Trial Readiness from the Viewpoint of Clinicians and Infrastructure
- ACTION ALERT: Make Your Voice Heard on New Healthcare Proposal
- PPMD's Duchenne Drug Development Roundtable Meeting Series, Part 2: Optimizing Clinical Trials
- PPMD Designates Ann & Robert H. Lurie Children's Hospital of Chicago a Certified Duchenne Care Center
- Marathon Pharmaceuticals Pauses Commercialization of EMFLAZA™ (deflazacort)
Latest Blog Posts
- Todlers Language and Speech Delays
- Celebrex is seen effective in DMD Mice
- Capricor Announces New Pre-Clinical Study Finds Repeat Doses of CAP-1002 Lead to Enhanced Exercise Capacity in Duchenne Muscular Dystrophy Disease Model
- PPMD & NIH to Host “Contractures in Duchenne and Other Neuromuscular Conditions”
- Solid Biosciences Provides Update On SGT-001 Clinical Development Program For Duchenne
- Pfizer Doses First Patient Using Investigational Mini-Dystrophin Gene Therapy for the Treatment of Duchenne Muscular Dystrophy
- 70 Members of Congress Send Letter of Strong Support for Duchenne Priorities for Next Year’s Budget
Most Popular Blog Posts
- April 25: FDA Advisory Committee Meeting for Eteplirsen - Live Webcast Information
- FDA Grants Accelerated Approval to First Drug for Duchenne Muscular Dystrophy
- September 28: FDA Advisory Committee Meeting for Ataluren - Live Webcast Information
- Changing the Paradigm: The Eteplirsen Ad Comm
- Deflazacort Approved in the U.S. for Duchenne
- A Historic Day for Duchenne
- Early morning calls
Monthly Archives
2019
- July (1)
2018
2017
- December (27)
- November (22)
- October (18)
- September (20)
- August (8)
- July (7)
- June (14)
- May (17)
- April (17)
- March (14)
- February (14)
- January (18)
2016
- December (13)
- November (10)
- October (26)
- September (15)
- August (16)
- July (10)
- June (13)
- May (12)
- April (17)
- March (18)
- February (20)
- January (23)
2015
- December (28)
- November (13)
- October (23)
- September (20)
- August (17)
- July (23)
- June (18)
- May (11)
- April (13)
- March (25)
- February (17)
- January (22)
2014
- December (18)
- November (13)
- October (18)
- September (16)
- August (10)
- July (21)
- June (18)
- May (18)
- April (50)
- March (32)
- February (10)
- January (12)
2013
- December (33)
- November (86)
- October (28)
- September (17)
- August (11)
- July (17)
- June (16)
- May (20)
- April (18)
- March (29)
- February (25)
- January (21)
2012
- December (14)
- November (21)
- October (35)
- September (31)
- August (28)
- July (19)
- June (16)
- May (26)
- April (24)
- March (33)
- February (26)
- January (18)
2011
- December (15)
- November (25)
- October (26)
- September (20)
- August (12)
- July (15)
- June (12)
- May (11)
- April (16)
- March (14)
- February (15)
- January (24)
2010
- December (24)
- November (11)
- October (11)
- September (11)
- August (20)
- July (15)
- June (14)
- May (19)
- April (15)
- March (20)
- February (17)
- January (27)
2009
- December (22)
- November (32)
- October (9)
- September (15)
- August (18)
- July (13)
- June (10)
- May (13)
- April (18)
- March (26)
- February (15)
- January (15)
2008
2007
© 2019 Created by PPMD.
Powered by
Badges | Report an Issue | Privacy Policy | Terms of Service
